SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,450.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 180.00 (4.091%)
Market Cap: £296.40m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Trading Statement

18 Jul 2013 07:00

RNS Number : 5740J
Judges Scientific PLC
18 July 2013
 

 

 

Judges Scientific plc

Trading Statement

 

18 July 2013

 

Judges Scientific plc ('Judges Scientific', the 'Company' or the 'Group')

 

Trading Update

 

The Directors of Judges Scientific, the parent company of a group specialising in the design, manufacture and sale of scientific instruments, are pleased to update shareholders and the market with regard to the Group's trading performance during the first half of the current financial year.

The interim Income Statement for the six months to 30 June 2013 will not include any results from Scientifica Ltd ("Scientifica"), which was acquired on 26 June 2013 and represents the Group's largest acquisition to date. The interim Balance Sheet will reflect the acquisition.

The Group's businesses delivered a satisfactory trading performance during the period. The interim results, scheduled to be announced in September, are expected to show revenue growth of 14% compared with the six months to 30 June 2012; this includes organic growth of 4.4% and the effect of a full six-month contribution from Global Digital Systems ("GDS") and KE Developments ("KED") compared with a four-month contribution in the first half of 2012. The Board anticipates that interim profits before exceptional items will reflect this satisfactory sales performance. Adjusted basic earnings per share are also expected to advance, despite the 20% dilution resulting from the May 2012 share issue and the conversion of most of the convertible redeemable shares in the second half of 2012.

Order intake during the six-month period showed only slight organic growth, with a strong first quarter being followed by a weak second quarter. Had GDS and Scientifica been part of Judges throughout the first-half periods of both 2012 and 2013, the Group as presently constituted would have shown 13% growth in order intake for the period. The order book at 30 June 2013 (excluding Scientifica) represented 10.6 weeks of sales, somewhat ahead of the 10-week level at 30 June 2012.

Operating cash flow was healthy during the period. The interim Balance Sheet will show the impact of the Scientifica acquisition and of the majority of the building cost of the Stonecross property; net debt still rests at a prudent multiple of operating profit.

Several other companies in our sector have recently reported challenging conditions and our own markets have not been uniformly positive. However, the resilience of Judges' diversified business activities has enabled the Company to continue to pursue its objectives in a lacklustre environment.

 

 

For further information please contact:

Judges Scientific Plc

David Cicurel, CEO

Tel: 01342 323 600

 

Shore Capital (Nominated Adviser & Broker)

Pascal Keane

Edward Mansfield

Tel: 020 7408 4090

 

Cardew Group (Financial Public Relations)

Melvyn Marckus

Tel: 020 7930 0777 or 07775 896 491

 

Websites:

Judges Scientific: www.judges.uk.com 

Scientifica: http: www.scientifica.uk.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMGMNVNNGFZM
Date   Source Headline
23rd May 202211:00 amRNSPrice Monitoring Extension
23rd May 20227:00 amRNSAcquisition of Geotek and new banking facilities
10th May 20223:59 pmRNSDirector/PDMR Shareholding
29th Apr 20229:13 amRNSNotice of AGM
25th Apr 20224:41 pmRNSHolding(s) in Company
22nd Apr 20223:37 pmRNSDirector/PDMR Shareholding
30th Mar 20223:26 pmRNSTotal Voting Rights
23rd Mar 20227:00 amRNSFinal Results
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
23rd Feb 202210:44 amRNSDirector/PDMR Shareholding
14th Jan 202211:42 amRNSDirector/PDMR Shareholding
7th Jan 20227:00 amRNSFull Year Trading Statement and Notice of Results
8th Dec 20217:00 amRNSDirector/PDMR Shareholding
1st Dec 20219:57 amRNSTotal Voting Rights
30th Nov 20218:27 amRNSDirector/PDMR Shareholding
12th Nov 202111:10 amRNSDirector/PDMR Shareholding
10th Nov 20216:07 pmRNSDirector/PDMR Shareholding
1st Nov 20217:00 amRNSTotal Voting Rights
8th Oct 20219:26 amRNSDirector/PDMR Shareholding
28th Sep 20212:29 pmRNSDirector/PDMR Shareholding
24th Sep 20217:00 amRNSInterim Results
7th Sep 20212:20 pmRNSDirector/PDMR Shareholding
1st Sep 20212:34 pmRNSTotal Voting Rights
16th Aug 20217:00 amRNSDirector/PDMR Shareholding
2nd Aug 202112:19 pmRNSTotal Voting Rights
27th Jul 202111:29 amRNSDirector/PDMR Shareholding
22nd Jul 20217:00 amRNSHalf Year Trading Update and Notice of Results
9th Jul 202111:50 amRNSDirector/PDMR Shareholding
1st Jul 20217:00 amRNSTotal Voting Rights
10th Jun 20211:38 pmRNSBlock listing Interim Review
10th Jun 20219:49 amRNSDirector/PDMR Shareholding
28th May 20215:28 pmRNSPurchase of Ordinary Shares
28th May 20217:00 amRNSTotal Voting Rights
26th May 202112:53 pmRNSResult of AGM
26th May 20217:00 amRNSNew £60.0 million Bank Facility
20th May 202112:00 pmRNSAGM Q&A
11th May 20214:53 pmRNSDirector/PDMR Shareholding
10th May 20218:21 amRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSTotal Voting Rights
29th Apr 202111:59 amRNSNotice of AGM
13th Apr 202111:39 amRNSDirector/PDMR Shareholding
1st Apr 202111:28 amRNSTotal Voting Rights
25th Mar 202111:58 amRNSDirector/PDMR Shareholding
23rd Mar 20217:00 amRNSFinal Results
10th Mar 20217:00 amRNSDirector/PDMR Shareholding
26th Feb 20217:00 amRNSTotal Voting Rights
16th Feb 20217:00 amRNSIncreased shareholding in Bordeaux Acquisition Ltd
9th Feb 20211:27 pmRNSDirector/PDMR Shareholding
29th Jan 20217:00 amRNSTotal Voting Rights
19th Jan 202111:57 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.